ASSEMBLY, No. 2795

STATE OF NEW JERSEY

220th LEGISLATURE

INTRODUCED FEBRUARY 28, 2022

Sponsored by:

Assemblyman HERB CONAWAY, JR.
District 7 (Burlington)
Assemblyman DANIEL R. BENSON
District 14 (Mercer and Middlesex)
Assemblyman JOE DANIELSEN
District 17 (Middlesex and Somerset)


Co-Sponsored by:

Assemblymen Mukherji, Simonsen and McClellan

SYNOPSIS

Expands requirements for health insurance carriers concerning prostate cancer screening and requires coverage be provided without cost sharing.

CURRENT VERSION OF TEXT



(Sponsorship Updated As Of: 6/16/2022)

AN ACT concerning health insurance coverage for prostate cancer screening and amending P.L.1996, c.125 and supplementing various parts of the statutory law.

4 5

BE IT ENACTED by the Senate and General Assembly of the State of New Jersey:

6 7 8

9

23

24

25

26

27

28

29

30

31

3233

3435

36

37

- 1. Section 1 of P.L.1996, c.125 (C.17:48E-35.13) is amended to read as follows:.
- 10 1. <u>a.</u> No health service corporation contract providing hospital or medical expense benefits [for groups with greater than 49] 11 persons] shall be delivered, issued, executed or renewed in this 12 13 State, or approved for issuance or renewal in this State by the 14 Commissioner of Insurance on or after the effective date of **[**this act P.L.1996, c.125 (C.17:48E-35.13 et al.), unless the contract 15 16 provides benefits to any named subscriber or other person covered 17 thereunder for expenses incurred in conducting an annual Imedically recognized diagnostic examination including, but not 18 19 limited to, a digital rectal examination and a prostate-specific antigen test for men age 50 and over who are asymptomatic and for 20 men age 40 and over with a family history of prostate cancer or 21 22 other prostate cancer risk factors prostate cancer screening.

The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the benefits shall be imposed.

This section shall apply to all health service corporation contracts in which the health service corporation has reserved the right to change the premium.

b. As used in this section:

- "Prostate cancer screening" means medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a health care provider, including, but not limited to:
- (1) urinary analysis;
- 38 (2) serum biomarkers;
- 39 (3) medical imaging, including, but not limited to, magnetic 40 resonance imaging.
- 41 (cf: P.L.1996, c.125, s.1)

42

2. Section 2 of P.L.1996, c.125 (C.17:48-6p) is amended to read as follows:

EXPLANATION – Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted in the law.

1 2. a. No hospital service corporation contract providing hospital 2 or medical expense benefits [for groups with greater than 49] 3 persons] shall be delivered, issued, executed or renewed in this 4 State, or approved for issuance or renewal in this State by the 5 Commissioner of Insurance on or after the effective date of [this act P.L.1996, c.125 (C.17:48E-35.13 et al.), unless the contract 6 7 provides benefits to any named subscriber or other person covered 8 thereunder for expenses incurred in conducting an annual 9 Imedically recognized diagnostic examination including, but not 10 limited to, a digital rectal examination and a prostate-specific 11 antigen test for men age 50 and over who are asymptomatic and for 12 men age 40 and over with a family history of prostate cancer or 13 other prostate cancer risk factors prostate cancer screening.

The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the benefits shall be imposed.

This section shall apply to all hospital service corporation contracts in which the hospital service corporation has reserved the right to change the premium.

b. As used in this section:

"Prostate cancer screening" means medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a health care provider, including, but not limited to:

- (1) urinary analysis;
- (2) serum biomarkers;
- 30 (3) medical imaging, including, but not limited to, magnetic resonance imaging.
- 32 (cf: P.L.1996, c.125, s.2)

33

34

35

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

- 3. Section 3 of P.L.1996, c.125 (C.17:48A-7n) is amended to read as follows:
- 36 3. a. No medical service corporation contract providing hospital 37 or medical expense benefits [for groups with greater than 49] 38 persons] shall be delivered, issued, executed or renewed in this 39 State, or approved for issuance or renewal in this State by the 40 Commissioner of Insurance on or after the effective date of **[**this 41 act P.L.1996, c.125 (C.17:48E-35.13 et al.), unless the contract 42 provides benefits to any named subscriber or other person covered 43 thereunder for expenses incurred in conducting an annual 44 Imedically recognized diagnostic examination including, but not 45 limited to, a digital rectal examination and a prostate-specific 46 anitgen test for men age 50 and over who are asymptomatic and for

1 men age 40 and over with a family history of prostate cancer or 2 other prostate cancer risk factors prostate cancer screening.

The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the benefits shall be imposed.

This section shall apply to all medical service corporation contracts in which the medical service corporation has reserved the right to change the premium.

b. As used in this section:

"Prostate cancer screening" means medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a health care provider, including, but not limited to:

- (1) urinary analysis;
- (2) serum biomarkers;
- 19 (3) medical imaging, including, but not limited to, magnetic 20 resonance imaging.
- 21 (cf: P.L.1996, c.125, s.3)

2223

24

25

26

27

2829

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

7

8

9

10

11

12

13

1415

16

17

18

- 4. Section 4 of P.L.1996, c.125 (C.17B:27-46.10) is amended to read as follows:
- 4. a. No group health insurance policy providing hospital or medical expense benefits [for groups with greater than 49 persons] shall be delivered, issued, executed or renewed in this State, or approved for issuance or renewal in this State by the Commissioner of Insurance on or after the effective date of [this act] P.L.1996, c.125 (C.17:48E-35.13 et al.), unless the policy provides benefits to any named insured or other person covered thereunder for expenses incurred in conducting an annual [medically recognized diagnostic examination including, but not limited to, a digital rectal examination and a prostate-specific antigen test for men age 50 and over who are asymptomatic and for men age 40 and over with a family history of prostate cancer or other prostate cancer risk factors] prostate cancer screening.

The benefits shall be provided to the same extent as for any other medical condition under the policy except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the benefits shall be imposed.

This section shall apply to all group health insurance policies in which the health insurer has reserved the right to change the premium.

b. As used in this section:

46 <u>"Prostate cancer screening" means medically viable methods for
 47 <u>the detection and diagnosis of prostate cancer, which includes a</u>
</u>

- 1 <u>digital rectal exam and the prostate-specific antigen test and</u>
- 2 <u>associated laboratory work. "Prostate cancer screening" shall also</u>
- 3 <u>include subsequent follow up testing as direct by a health care</u>
- 4 provider, including, but not limited to:
 - (1) urinary analysis;
 - (2) serum biomarkers;
- 7 (3) medical imaging, including, but not limited to, magnetic resonance imaging.
- 9 (cf: P.L.1996, c.125, s.4)

10

24

25

26

27

28

29

30

31

32

33

34

35

3637

38

39

40

5

6

- 11 5. Section 5 of P.L.1996, c.125 (C.26:2J-4.13) is amended to read as follows:
- 13 5. a. A certificate of authority to establish and operate a health 14 maintenance organization in this State shall not be issued or 15 continued by the Commissioner of Health on or after the effective 16 date of [this act] P.L.1996, c.125 (C.17:48E-35.13 et al.) unless the 17 health maintenance organization provides health care services to 18 any enrollee which include an annual [medically recognized 19 diagnostic examination including, but not limited to, a digital rectal 20 examination and a prostate-specific antigen test for men age 50 and 21 over who are asymptomatic and for men age 40 and over with a 22 family history of prostate cancer or other prostate cancer risk 23 factors] prostate cancer screening.
 - The health care services shall be provided to the same extent as for any other medical condition under the contract except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the services shall be imposed.
 - The provisions of this section shall apply to all contracts for health care services by health maintenance organizations under which the right to change the schedule of charges for enrollee coverage is reserved.
 - b. As used in this section:
 - "Prostate cancer screening" means medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as directed by a health care provider, including, but not limited to:
 - (1) urinary analysis;
 - (2) serum biomarkers;
- 41 (3) medical imaging, including, but not limited to, magnetic 42 resonance imaging.
- 43 (cf: P.L.1996, c.125, s.5)

44

6. (New section) a. (1) Every individual health insurance policy that provides hospital or medical expense benefits and is delivered, issued, executed or renewed in this State pursuant to chapter 26 of Title 17B of the New Jersey Statutes, or approved for

issuance or renewal in this State by the Commissioner of Banking and Insurance, on or after the effective date of this act shall provide coverage for an annual prostate cancer screening.

The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the services shall be imposed.

The provisions of this section shall apply to all policies in which the insurer has reserved the right to change the premium.

b. As used in this section:

"Prostate cancer screening" means medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a health care provider, including, but not limited to:

- (1) urinary analysis;
- (2) serum biomarkers;
- (3) medical imaging, including, but not limited to, magnetic resonance imaging.

202122

23

24

25

26

27

2829

30

31

32

33

34

35

3637

38 39

40

41

42

43

44

4 5

6

7

8

10

11

12

13

1415

16

17

18

19

- 7. (New section) a. (1) Every individual health benefits plan that provides hospital or medical expense benefits and is delivered, issued, executed or renewed in this State pursuant to P.L.1992, c.161 (C.17B:27A-2 et seq.) or approved for issuance or renewal in this State on or after the effective date of this act shall provide benefits for an annual prostate cancer screening.
- The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the services shall be imposed.
- The provisions of this section shall apply to all health benefits plans in which the carrier has reserved the right to change the premium.
 - b. As used in this section:
- "Prostate cancer screening" means medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a health care provider, including, but not limited to:
 - (1) urinary analysis;
 - (2) serum biomarkers;
- (3) medical imaging, including, but not limited to, magnetic resonance imaging.

45 46 47

48

8. (New section) a. Every small employer health benefits plan that provides hospital or medical expense benefits and is delivered,

- issued, executed or renewed in this State pursuant to P.L.1992, c.162 (C.17B:27A-17 et seq.) or approved for issuance or renewal in this State on or after the effective date of this act shall provide
- 4 benefits for an annual prostate cancer screening.

The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the services shall be imposed.

The provisions of this section shall apply to all health benefits plans in which the carrier has reserved the right to change the premium.

b. As used in this section:

"Prostate cancer screening" means medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a physician, including, but not limited to:

- (1) urinary analysis;
- (2) serum biomarkers;
- 21 (3) medical imaging, including, but not limited to, magnetic resonance imaging.

2324

25

26

27

28

29

30

31

32

33

34

35

3637

38 39

40

41

42

5

6

7

8

9

10

11 12

13

1415

16 17

18 19

20

- 9. (New section) a. The State Health Benefits Commission shall ensure that every contract purchased by the commission on or after the effective date of this act that provides hospital or medical expense benefits shall provide coverage for an annual prostate cancer screening.
- The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the services shall be imposed.
 - b. As used in this section:

"Prostate cancer screening" means medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a health care provider, including, but not limited to:

- (1) urinary analysis;
- (2) serum biomarkers;
- (3) medical imaging, including, but not limited to, magnetic resonance imaging.

434445

46

47

10. (New section) a. The School Employees' Health Benefits Commission shall ensure that every contract purchased by the commission on or after the effective date of this act that provides

hospital or medical expense benefits shall provide coverage for an
 annual prostate cancer screening.

The benefits shall be provided to the same extent as for any other medical condition under the contract except that no deductible, coinsurance, copayment, or any other cost-sharing requirement on the services shall be imposed.

b. As used in this section:

"Prostate cancer screening" means medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a health care provider, including, but not limited to:

- (1) urinary analysis;
- (2) serum biomarkers;
- (3) medical imaging, including, but not limited to, magnetic resonance imaging.

11. This act shall take effect on the 90th day next following the date of enactment and shall apply to all contracts and policies delivered, issued, executed, or renewed on or after that date.

2223

24

3

4 5

6 7

8

9 10

11

12

13 14

15

16

17

18 19

20

21

STATEMENT

2526

27

2829

30

31

32

33

34

35

3637

38 39

40

41

42

43

46

47

48

This bill requires health, hospital, and medical service corporations, health maintenance organizations, and commercial group health insurers to provide coverage for an annual prostate cancer screening without cost sharing. Under current law, these health insurance carriers are required only to provide coverage for an annual medically recognized diagnostic examination including, but not limited to, a digital rectal examination and a prostatespecific antigen test for men age 50 and over who are asymptomatic and for men age 40 and over with a family history of prostate cancer or other prostate cancer risk factors. The bill expands the definition of "prostate cancer screening" to mean medically viable methods for the detection and diagnosis of prostate cancer, which includes a digital rectal exam and the prostate-specific antigen test and associated laboratory work. "Prostate cancer screening" shall also include subsequent follow up testing as direct by a physician, including, but not limited to:

- (1) urinary analysis;
- (2) serum biomarkers;
- 44 (3) medical imaging, including, but not limited to, magnetic resonance imaging.

The bill also extends the prostate cancer screening requirements to commercial individual health insurers, health benefits plans issued pursuant to the New Jersey Individual Health Coverage and

A2795 CONAWAY, BENSON

q

- 1 Small Employer Health Benefits Programs, the State Health
- 2 Benefits Program, and the School Employees' Health Benefits
- 3 Program, which are not required to provide this coverage under
- 4 current law.